Palvella Therapeutics raises ~$187.3M in public offering of 1.6M shares at $125/sh

PALVELLA THERAPEUTICS, INC.

Underwriting agreement with TD Securities, Cantor Fitzgerald, and Stifel for 1,600,000 shares at $125.00 each.
Underwriters have 30-day option to purchase up to an additional 240,000 shares at same price.
Net proceeds estimated at $187.3M after underwriting discounts and expenses.
Proceeds to support QTORIN rapamycin and pitavastatin programs, R&D, and working capital.
Closing expected on or about February 27, 2026, subject to customary conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PALVELLA THERAPEUTICS, INC. entered into Underwriting Agreement with TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated valued at approximately $187.3 million (effective 2026-02-25).

Action: entry
Agreement: underwriting
Counterparty: TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated
Value: approximately $187.3 million
Effective: 2026-02-25

Exact text from the filing

On February 25, 2026, Palvella Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated, as representatives (the “Representatives”) of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 1,600,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), at a price to the public of $125.00 (the “Offering”).

View on SEC.gov

291 material agreements filed in the last 30 days. Browse all material agreements →

PALVELLA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-020667

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.